MGC Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGCLF research report →
Price Chart
About the company
MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics. Among its key investigational drug candidates are CimetrA, which is undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19; CannEpil, a Phase IIb cannabis-based therapy targeting drug-resistant epilepsy; and CogniCann, currently in Phase II clinical evaluation for the symptomatic relief of dementia.
- CEO
- Roby Reuven Zomer
- IPO
- 2017
- HQ
- West Perth, WA, AU
Get TickerSpark's AI analysis on MGCLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.11M
- P/E
- -0.06
- PEG
- -0.00
- P/S
- 5.44
- P/B
- -0.17
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
- Gross Margin
- 37.96%
- Op Margin
- -457.29%
- Net Margin
- -614.64%
- ROE
- 2660.08%
- ROIC
- -257.29%
Latest fiscal year · YoY change
- Revenue
- $3.39M-28.4%
- Gross Profit
- $1.29M-17.7%
- Op Income
- $-15,493,000
- Net Income
- $-20,824,000-2.3%
- EPS
- $-7.10+10.1%
- OCF Growth
- +1.4%
- FCF Growth
- +18.0%
- 52W High
- $5.10
- 52W Low
- $0.23
- 50D MA
- $0.27
- 200D MA
- $0.58
- Beta
- 0.97
- RSI (14)
- 10
- Avg Volume
- 192
No earnings-call transcripts are available for MGCLF yet.
- Free Float
- 47.2%
- Shares Outstanding
- 45.28M
- Float Shares
- 21.35M
Our MGCLF coverage
Recent articles, reports, and earnings notes.
No research on MGCLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MGCLF report →Argent BioPharma hails US listing; appoints new CFO
proactiveinvestors.co.uk · May 7
MGC Pharma reports progress 'across all fronts'
proactiveinvestors.com · Feb 29
MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation
prnewswire.com · Feb 13
MGC Pharmaceuticals unveils fundraise as global push planned
proactiveinvestors.com · Dec 22
MGC Pharmaceuticals granted Saudi FDA approval for ArtemiC™
proactiveinvestors.com · Dec 19
MGC Pharma receives Saudi approval for ArtemiC
proactiveinvestors.com · Dec 19
MGC Pharmaceuticals clarifies share consolidation and new fundraise
proactiveinvestors.com · Nov 1
MGC Pharmaceuticals proposes financial and capital restructuring plan
proactiveinvestors.com · Sep 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.